Evidence Hub

Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference

Mark Obermann, Naegel

Neuropsychiatric Disease and Treatment, 2009

38 citations

Abstract

Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference Steffen Naegel, Mark ObermannDepartment of Neurology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, GermanyAbstract: Migraine is a very common disorder characterized by the combination of typical headache with associated autonomic symptoms and/or the presence of aura. Considerable advances have been made in recent years to understand the pathophysiology of migraine, which has led to improved treatment options for the acute migraine attack as well as migraine prophylaxis. Unfortunately, preventive treatment is often insufficient to decrease migraine frequency substantially or is not well tolerated. Topiramate is an antipileptic drug with a complex mode of action which has proven its efficacy and safety in the prophylactic treatment of episodic migraine in a number of randomized controlled clinical trials. Topiramate is also effective in treating patients with chronic migraine. It has little pharmacological interaction with other drugs and is generally well tolerated by patients.Keywords: migraine, antiepileptic drugs, topiramate

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free